The DOI matches its Crossref record; 551 of the 559 references it cites were found in a registry or an index.
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Open accessAbstract
The aim of this article is to describe the current and potential clinical translation of pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases. The first section of the present review summarizes the available preclinical and clinical data with PARP inhibitors in various forms of cancer. In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-associated lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer. HRR defects are classically associated with BRCA1 and 2 mutations associated with familial breast and ovarian cancer, but there may be many other causes of HRR defects. Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects. Multiple lines of preclinical data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation. Both single agent and combination clinical trials are underway. The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clinical development. The second section of the present review summarizes the role of PARP in selected non-oncologic indications. In a number of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clinical translatability of PARP inhibition is supported by multiple lines of preclinical data, as well as observational data demonstrating PARP activation in human tissue samples. In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathology. Accordingly, multiple lines of preclinical data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses. As the clinical trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clinical investigations, aimed at testing of PARP inhibitors for various non-oncologic indications, will be initiated, as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“specific pharmacological inhibitors of PARP1 efficiently delay parthanatos in multiple cell types, in vitro and in vivo [1, 669].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [669]
In the citing paper
“PARP1 inhibition by pharmacological or genetic interventions mediates robust cytoprotective effects in multiple animal models of disease [1, 669].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [669]
In the citing paper
“PARP inhibitors (Paribs) already exist and are clinically tested in the cancer field (Curtin and Szabo, 2013).”
From Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle (2014) · cites this paper as Curtin and Szabo, 2013
In the citing paper
“Paribs are currently being tested for oncology indications, with positive outcomes in tumors with dysfunctional homologous DNA recombination repair (Curtin and Szabo, 2013).”
From Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle (2014) · cites this paper as Curtin and Szabo, 2013
In the citing paper
“The success of Paribs is thought to rely on the high dependency of these cancer cells on PARP enzymes for DNA repair (Curtin and Szabo, 2013), but could also involve their capacity to reprogram cells towards oxidative metabolism (Bai et al., 2011).”
From Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle (2014) · cites this paper as Curtin and Szabo, 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cuzzocrea, S., Zingarelli, B., Gilad, E., Hake, P. W., Salzman, A. L., & Szabó, C. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01417-9 · Cited by 85
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Yarbrough, W. M., Robbins, R. C., & Mallidi, H. R. (2016) · CRC Press eBooks · doi:10.3109/9781439802571-25 · Cited by 2,161
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Szabó, C., Ischiropoulos, H., & Radi, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2222 · Cited by 2,134
Self-citation
Flagged first, then by citations
8 of the 559 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Du, 2007, Local administration of the poly (ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice, J. Neurotrauma, 24, 1399, 10.1089/neu.2007.0305 · DOI
- Komjáti, 2005, Poly(ADP-ribose) polymerase inhibitors as therapeutic agents for stroke and brain trauma. Current Drug Targets, CNS Neurol. Disord., 4, 179
- Miknyoczki, 2003, Chemopotentiation of temozlomide, irinotecan and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor, Mol. Cancer Ther., 2, 371
Cited by
Sorted by citations
Items 301–391 of 391
Plant-derived diterpenes for breast cancer treatment: New perspectives and recent advances
Tomiotto‐Pellissier, F., Gonçalves, M. D., Silva, T. F., Concato, V. M., Bortoleti, B. T. D. S., Arakawa, N. S., Costa, I. C., Pavanelli, W. R., & Panis, C. (2022) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91099-6.00011-6 · Cited by 4
Shram, S. I., Shcherbakova, T. A., Abramova, T. V., Baradieva, E. C., Efremova, A. S., Smirnovskaya, M. S., Silnikov, V. N., Švedas, V. K., & Nilov, D. K. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923060068 · Cited by 4
Mechanistic paradigms of cell death - revisited
Rana, S. V. S. (2021) · Journal of Environmental Biology · doi:10.22438/jeb/42/4/mrn-1965 · Cited by 3
Recent PARP Inhibitor Advancements in Cancer Therapy: A Review
Byran, G., Raj, P. P., Lakshmanan, K., Rajagopal, K., Krishnamurthy, P. T., & Palati, D. J. (2022) · Current Enzyme Inhibition · doi:10.2174/1573408018666220321115033 · Cited by 3
Cardiac dysfunction as a result of cancer treatment
Myatt, R. (2015) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2015.10.2.86 · Cited by 3
Slade, D., & Eustermann, S. (2020) · Science · doi:10.1126/science.abb1462 · Cited by 3
Che, L., Song, J., Lou, Y., & Li, G. (2019) · International Ophthalmology · doi:10.1007/s10792-019-01245-y · Cited by 3
Rahman, A., Nippu, B. N., Siddappa, M. K., Jain, S. K., Honnenahally, K. M., Achur, R. N., Satyanarayan, N. D., & Mahadevan, K. M. (2022) · ChemistrySelect · doi:10.1002/slct.202204309 · Cited by 4
Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on GlioblastomaPreprint
Hermanowski, H. M., Huebert, B., Aldrighetti, C. M., Hurley, J. K., & Quénet, D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.30.180216 · Cited by 3
Tu, J., Chen, J., Zhou, N., & Luo, L. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11238-y · Cited by 2
Latif, M. A. M., Mazhar, S., Tasleem, M., Alqurashi, A. A., Arfan, M., , Z. A., & Zafar, M. B. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s575152 · Cited by 2
Zheng, Y., Kong, D., Huynh, T. T., Zhao, X., Liu, Y.-C., Banks, R. L., Vaidyanathan, G., Feng, Y., & Zalutsky, M. R. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00367 · Cited by 2
Ceisel, A., Graziano, G., Emmerich, K., Shi, X., Kam, T., Flores‐Bellver, M., Vergara, M. N., Aparicio‐Domingo, S., Brenerman, B. M., Vielle, A., et al. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052747 · Cited by 2
Farhana, F., Sakai, E., Koyanagi, Y., Yamaguchi, Y., Alam, M. I., Okamoto, K., & Tsukuba, T. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08690-0 · Cited by 2
Oit-Wiscombe, I., Soomets, U., & Altraja, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030149 · Cited by 2
In Vivo Level of Poly(ADP-ribose)
Miwa, M., Ida, C., Yamashita, S., Kouyama, K., Kuroda, Y., Eguchi, T., Ohta, N., Sato, T., Tsuda, M., & Tanaka, M. (2018) · Challenges · doi:10.3390/challe9010023 · Cited by 2
Targeting DNA Damage Response Pathways in Cancer
Abdulrahman, G. O., & Curtin, N. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12394-7 · Cited by 2
Self-citationShram, S. I., Shcherbakova, T. A., Abramova, T. V., Baradieva, E. C., Efremova, A. S., Smirnovskaya, M. S., Silnikov, V. N., Švedas, V. K., & Nilov, D. K. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523060064 · Cited by 2
A New Approach in Cancer Treatment: Poly(ADP-Ribose) Polymerase-1 Inhibitors
Tok, F., & Koçyiğit‐Kaymakçıoğlu, B. (2015) · Clinical and Experimental Health Sciences · doi:10.5455/musbed.20141015015238 · Cited by 2
Hypoxia in Head and Neck Cancer: Current Relevance
Féron, O. (2025) · Springer eBooks · doi:10.1007/978-3-031-84539-0_13 · Cited by 2
Doberstein, K., Panther, J., Hahnen, E., Richters, L., Schouten, P. C., Harter, P., Heitz, F., Kommoss, S., Berlit, S., Tuschy, B., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08836-9 · Cited by 1
Preclinical Chemosensitization by PARP Inhibitors
Shalinsky, D. R., Donawho, C. K., Los, G., & Palma, J. P. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_9 · Cited by 1
Role of YB-1 in Regulation of Poly(ADP-Ribosylation) Catalyzed by Poly(ADP-Ribose) Polymerases
Alemasova, E. E., Naumenko, K. N., Sukhanova, M. V., & Lavrik, O. I. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922140048 · Cited by 1
PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
Sharif-Askari, B., Panasci, L., & Aloyz, R. S. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2803052 · Cited by 1
4-Hexylresorcinol as Histone Deacetylase Inhibitor
Kim, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-0637-2_5 · Cited by 1
Oxidative stress and PARP activation in the lungs is an early event in COVID-19 pneumonia
Juhász, P., Bohus, P., Sipos, A., Curtin, N. J., Méhes, G., & Bai, P. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.06.010 · Cited by 1
Self-citationDynamic Properties of Skeletal Muscle Contraction in Rats with Diabetes
Beregova, T. V., Nozdrenko, D. M., Berehovyi, S. M., Никитина, Н. С., Falalyeyeva, T. M., & Остапченко, Л. І. (2018) · InTech eBooks · doi:10.5772/intechopen.70600 · Cited by 1
Precision medicine for the treatment of triple negative breast cancer: opportunities and challenges
Sadiq, M. T., Servante, J., & Madhusudan, S. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1920834 · Cited by 1
Ononye, S. N. (2013) · OpenCommons at University of Connecticut (University of Connecticut) · Cited by 1
The Important Role of Breast Microbiota in Breast CancerPreprint
Su, K.-Y., Lee, W.-L., & Balasubramaniam, V. R. M. T. (2020) · Preprints.org · doi:10.20944/preprints202010.0437.v1
Pelargonidin as an Attenuator of Neuronal Mitochondrial Dysfunction: An in Vivo StudyPreprint
Rashed, E. R., El‐Hamoly, T., El‐Sheikh, M. M., & El‐Ghazaly, M. A. (2021) · Research Square · doi:10.21203/rs.3.rs-407161/v1 · Cited by 1
Emerging Role of NO-Mediated Therapeutics
McCrudden, C. M., & McCarthy, H. O. (2015) · Springer eBooks · doi:10.1007/978-3-319-13611-0_13
Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality
Leszczyńska, K. B., Temper, N., Bristow, R. G., & Hammond, E. M. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_14
Lindgren, A. E. G. (2015) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Targeting Cancer Stem Cells and the Tumor Microenvironment
Turdo, A., Todaro, M., & Stassi, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_16 · Cited by 1
NAD+ as a Pharmacological Tool to Boost Sirtuin Activity
Houtkooper, R. H. (2016) · Springer eBooks · doi:10.1007/978-94-024-0962-8_2
Sherstyuk, Y. V., Zakharenko, A. L., Kutuzov, M. M., Sukhanova, M. V., Lavrik, O. I., Silnikov, V. N., & Abramova, T. V. (2017) · Биоорганическая химия · doi:10.7868/s0132342317010109
Résistance aux inhibiteurs de PARP
Rodrigues, M. J., Manié, É., Cottu, P. H., Frank, S., Bellesœur, A., Bataillon, G., Popova, T. G., & Stern, M. (2019) · Innovations & Thérapeutiques en Oncologie · doi:10.1684/ito.2019.0161
[Poly adenosine diphosphate-ribosylation and neurodegenerative diseases].
Wáng, Y., & Lu, Y. (2020) · PubMed Central · doi:10.3785/j.issn.1008-9292.2020.02.10
Okunlola, F. O., Soremekun, O. S., Olotu, F. A., & Soliman, M. E. S. (2020) · Chemistry & Biodiversity · doi:10.1002/cbdv.202000802
Recapitulating Parkinson’s disease pathology in a three-dimensional neural cell culture model
Taylor-Whiteley, T. R. (2019) · Sheffield Hallam University · doi:10.7190/shu-thesis-00321
Shao, D., Zhou, H., Yu, H., Luo, P., Cheng, Z., & Zhu, X. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.065
RetractedLiu, X., Zhang, F., & Zhang, X. (2020) · doi:10.21203/rs.3.rs-26946/v1
de Haan, R., van den Heuvel, M. M., van Diessen, J., Peulen, H. M. U., van Werkhoven, E. D., de Langen, A. J., Lalezari, F., Pluim, D., Verwijs-Janssen, M., Vens, C., et al. (2023) · doi:10.1158/1078-0432.c.6529965
de Haan, R., van den Heuvel, M. M., van Diessen, J., Peulen, H. M. U., van Werkhoven, E. D., Langen, A. J. D., Lalezari, F., Pluim, D., Verwijs-Janssen, M., Vens, C., et al. (2023) · doi:10.1158/1078-0432.c.6529965.v1
Platov, D., Kozlova, A., Alexeev, C. S., & Drenichev, M. S. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008112
Yasmeen, Karhana, S., Baboota, S., Khan, M. A., & Ali, J. (2025) · Assay and Drug Development Technologies · doi:10.1089/adt.2024.083
Raj, P. P., Palati, D. J., Krishnamurthy, P. T., & Byran, G. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i4.54313
Repurposing of PARP Inhibitors for the Clinical Management of Acute Cardiotoxicity
Gallyas, F., Halmosi, R., & Toth, K. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_37
Koetle, M. J., Motaung, T. E., & Amoo, S. O. (2025) · Plant Biology · doi:10.1111/plb.70150
Targeting DNA damage response pathways in cancer
Torrado, C., Tan, H. N., & Yap, T. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00075-3
Rôle des miARN dans la régulation des fonctions plaquettaires
Dréano, E. (2016) · theses.fr (ABES) · doi:10.70675/7f34ffbbz8891z466bzacaez75b277e21002
Ru(II)‐Catalyzed Regioselective C8–H Sulfonamidation of Isoquinolones With Sulfonyl Azides
Kumari, S., Shaw, A. K., Rastogi, A., Kant, R., & Koley, D. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.70573
Bisoi, A., & Singh, P. C. (2026) · ChemPhysChem · doi:10.1002/cphc.70443
Aydın, G. (2025) · Kastamonu University Journal of Engineering and Sciences · doi:10.55385/kastamonujes.1824730
de Moraes, M. O., Carvalho, L. A. D. C., Mendonça, Y. C. D. P., da Silva, R. O., Nunes, C. J., Lima, K., Machado‐Neto, J. A., Rodrigues, T., Rebecca, V., Bertolotto, C., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00033
Leng, Y., Bao, W., Ma, C., Bao, R., Bao, Y., Zhai, Z., Htar, T. T., & Wang, L. (2026) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.6c00122 · Cited by 2
Hassan, B., Bíró, E., Rauch, B., Dull, K., Rebenku, I., Kókai, E., Péter, M., Balogh, G., Zouboulis, C. C., & Szántó, M. (2026) · Research Square · doi:10.21203/rs.3.rs-11026678/v1
BindingDB Entry 50043765: 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors.
BindingDB (2014) · UC San Diego · doi:10.7270/q2js9rx4
BindingDB (2022) · UC San Diego · doi:10.7270/q2nc64zs
BindingDB Entry 50010632: From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
BindingDB (2021) · UC San Diego · doi:10.7270/q21j9fbq
BindingDB (2020) · UC San Diego · doi:10.7270/q2sf2zn3
BindingDB (2017) · UC San Diego · doi:10.7270/q2k35wjr
BindingDB (2023) · UC San Diego · doi:10.7270/q2k93cjv
BindingDB (2014) · UC San Diego · doi:10.7270/q2sb477r
BindingDB Entry 50045756: Towards small molecule inhibitors of mono-ADP-ribosyltransferases.
BindingDB (2016) · UC San Diego · doi:10.7270/q23j3fpj
BindingDB Entry 50008828: Discovery of naphthacemycins as a novel class of PARP1 inhibitors.
BindingDB (2021) · UC San Diego · doi:10.7270/q2668hkd
Metadata
- Authors
- Curtin, N. J., & Szabo, C.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Curtin, Nicola J.
- ORCID
- Curtin, Nicola J.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 34
- Issue
- 6
- Pages
- 1217-1256
- ISSN
- 0098-2997 (ISSN-L)
- PMC
- PMC3657315
- OpenAlex
- W2017171454
- Cited by
- 369
- References
- 559
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 12 · 2023: 22 · 2022: 25 · 2021: 25 · 2020: 37 · 2019: 31 · 2018: 26 · 2017: 32 · 2016: 38 · 2015: 50 · 2014: 24 · 2013: 21
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Aspects of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- PARP inhibitors, poly(ADP-ribose) polymerase, synthetic lethality, homologous recombination deficiency, BRCA mutations, breast cancer, ovarian cancer, temozolomide combination therapy, topoisomerase inhibitors, ionizing radiation, oxidative stress, nitrative stress, necrosis, inflammation, stroke, neurotrauma, shock, acute myocardial infarction, clinical translation
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Neoplasms, Poly(ADP-ribose) Polymerases, Radiation-Sensitizing Agents, Stroke, Translational Research, Biomedical, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
